ESTRO 2021 Abstract Book

S186

ESTRO 2021

Materials and Methods This trial is a prospective, observational cohort study. At the beginning of the combined treatment, all patients with LA-NSCLC undergone screening tests with clinical history, physical examination, blood chemistry (including lipid dosage, cardiac markers as Troponin I, Prohormone of Brain Natriuretic Peptide, Creatine Kinase MB, Polymerase Chain Reaction), 12-leads ECG, echocardiographic examination and cardiac MRI. A weekly evaluation was detected during treatment with ECG and cardiac marker assays. ECG, echocardiographic examination and strain evaluation was performed at month 1 (M1) and months 3 (M3) after the end of CRT. Results This preliminary analysis included thirty-four patients. The median age was 69.5 years (range, 43-87). The median follow-up was 27.8 months with a minimum value of 20.5 months. Sixty-two percent of patients were in stage IIIA. Adenocarcinomas and squamous carcinomas were equally represented. Radiation therapy was delivered with a median total dose of 60 Gy with conventional fractionation, and all patients were treated with concurrent chemoradiation and in 65% of cases it was a platinum-based regimen. None of the bio-humoral markers changed during CRT from basal values to last week of treatment. No change of normal values of QTcB and QTcF were recorded throughout the treatment. No difference was recorded between normal baseline values and at months 3 for mean end-diastolic Volume (EDV; 109.5 vs. 102.4, p=0.099) and mean End-Systolic Volume (ESV; 48.5 vs. 48.4, p=0.967). Echocardiography Global Longitudinal Strain (GLS) and Ejection Fraction (EF) progressively decreased from baseline to M1 and M3. There was a strict correlation between GLS and FE reductions (at M1: p=0.034; at M3: p=0.018). No correlations emerged between GLS or EF and bio-humoral markers, QTcB and QTcF, the total EQD2 dose, the use of concurrent platinum-based chemotherapy, all risk factors such as hypertension, diabetes, dyslipidemia, familiarity, the Body Mass Index, age, smoking, all drug therapies intake and ASCVD score. No patients died of cardiovascular complications. Eight patients (23.5%) had a cardiovascular event at a median follow-up of 15.8 months after CRT and in all but one patient heart rhythm problems were recorded. Hearth failure affected one patient. Conclusion This preliminary data shown that a reduction in GLS was the only variation observed at month 1 and months 3 after CRT in patients with LA-NSCLC. These findings encourage us to continue the study collecting data that allow us to estimate the overall and individual incidence of any early cardiac event in these patients and to identify any variables that cause an increased risk of acute cardiac events. 1 German Cancer Research Center (DKFZ),Heidelberg, Germany, German Cancer Consortium (DKTK), partner site Dresden, Dresden, Germany; 2 OncoRay - Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Dresden, Germany; 3 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; 4 National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association / Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany; 5 Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus,Technische Universität Dresden, Dresden, Germany; 6 Department of Otorhinolaryngology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; 7 Department of Oral and Maxillofacial Surgery, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; 8 German Cancer Research Center (DKFZ), Heidelberg, Germany, German Cancer Consortium (DKTK), partner site Berlin, Berlin, Germany; 9 Charité University Medicine Berlin, Department of Radiooncology and Radiotherapy, Berlin, Germany; 10 German Cancer Research Center (DKFZ), Heidelberg, Germany, German Cancer Consortium (DKTK), partner site Essen, Essen, Germany; 11 Department of Radiotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany; 12 German Cancer Research Center (DKFZ), Heidelberg, Germany, German Cancer Consortium (DKTK), partner site Frankfurt, Frankfurt, Germany; 13 Department of Radiotherapy and Oncology, Goethe- University Frankfurt, Frankfurt, Germany; 14 German Cancer Research Center (DKFZ), Heidelberg, Germany, German Cancer Consortium (DKTK), partner site Freiburg, Freiburg, Germany; 15 Department of Radiation Oncology, Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany; 16 German Cancer Research Center (DKFZ), Heidelberg, Germany, German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany; 17 Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation Research in Oncology (NCRO), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Heidelberg, Germany; 18 Heidelberg Ion Therapy Center (HIT), Department of Radiation Oncology, University of Heidelberg Medical School, Heidelberg, Germany; 19 National Center for Tumor Diseases (NCT), University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Heidelberg, Germany; 20 Translational Radiation Oncology, University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Heidelberg, Germany; 21 Heidelberg Ion Therapy Center (HIT), Department of Radiation Oncology, University of Heidelberg Medical School, Heidelberg, Germany; 22 Clinical Cooperation Unit Radiation Oncology, University of Heidelberg Medical School and German Cancer Research Center (DKFZ), Heidelberg , Germany; 23 German Cancer Research Center (DKFZ), Heidelberg, Germany, German Cancer Consortium (DKTK), partner site Munich, Munich, Germany; 24 Department of Radiotherapy and Radiation Oncology, University Hospital, Ludwig-Maximilians-Universität, Munich, Germany; 25 Clinical Cooperation Proffered papers: Proffered papers 14: Hypoxia and tumour microenvironment OC-0277 A 6-gene signature for loco-regional control prognosis in HNSCC patients treated by PORT-C S. Patil 1,2 , A. Linge 1,2,3,4 , M. Grosser 5 , V. Gudziol 4,6 , A. Nowak 4,7 , I. Tinhofer 8,9 , V. Budach 8,9 , A. Sak 10,11 , M. Stuschke 10,11 , P. Balermpas 12,13 , C. Rödel 12,13 , H. Schäfer 14,15 , A. Grosu 14,15 , A. Abdollahi 16,17,18,19,20 , J. Debus 16,17,21,19,22 , U. Ganswindt 23,24 , C. Belka 23,24,25 , S. Pigorsch 23,26 , S.E. Combs 23,27,28 , D. Mönnich 29,30 , D. Zips 29,30 , G.B. Baretton 1,4,5,31 , M. Baumann 1,2,3 , M. Krause 1,2,3,4 , S. Löck 1,2,3,4